ImmunTraCkeR
Commercial- Indications
- Cancer immunotherapy monitoring
Company intelligence / Profile preview
ImmunID
Grenoble, Francepmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
ImmunID develops diagnostic and prognostic tools that analyze immune signatures using genome sequencing and immunogenetics. Their technologies enable early detection of subtle changes in the immune repertoire, supporting disease progression monitoring, therapy selection, and response assessment for pharmaceutical companies. They have patented platforms such as ImmunTraCkeR for precision immuno-oncology applications.
- Therapeutic areas
- Immunology
- Modalities
- Diagnostic toolGenomic analysis
- Industry
- Molecular Diagnostics
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ImmunID.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunID.